Gut microbiota dysbiosis promotes coronary heart disease comorbid with depression through lipopolysaccharides and Toll-like receptor 4Original paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study tested how gut dysbiosis drives coronary heart disease combined with depression (CHDWD), often called double-heart disease. Researchers focused on the bacterial product lipopolysaccharide (LPS) and the TLR4/MYD88/NF-kappaB inflammatory pathway. A rat CHDWD model was built with a high-fat diet, chronic unpredictable mild stress and coronary artery ligation. They then performed fecal microbiota transplantation, applied the TLR4 inhibitor TAK-242, and measured 16S rRNA microbiota, serum LPS and pathway proteins in heart and hippocampus.
Who was studied?
The work used 100 male Sprague-Dawley rats, six weeks old and about 220 grams, kept under specific-pathogen-free conditions in China. This was an animal and in-vivo study, not a human trial. The CHDWD model succeeded in 60% of operated rats, confirmed by weight loss, ECG ischemia, raised myocardial enzymes and dyslipidemia. Separate groups received healthy or diseased donor stool, TAK-242, or long-term healthy microbiota transplant. Typically 7 rats per group entered analysis after outlier exclusion.
What were the most important findings?
Diseased rats showed altered microbiota, including higher Desulfobacterota and Campylobacterota, lower Bacteroidetes and a raised Firmicutes/Bacteroidetes ratio. Escherichia-Shigella, Ruminococcus and Streptococcus fell, while Parabacteroides, Odoribacter and Staphylococcus rose. Transplanting diseased stool into healthy rats induced weight loss, dyslipidemia, ST-segment elevation, myocardial injury and depressive behavior, alongside elevated serum LPS. Diseased and FMT-diseased rats had increased TLR4, MYD88, NF-kappaBp65, IKKbeta and TNF-alpha and reduced IkappaB-alpha. TAK-242 and healthy-microbiota transplant reversed the LPS rise, inflammation, cardiac damage and depression.
What are the greatest implications of this study?
The results suggest gut dysbiosis can help initiate double-heart disease by raising systemic LPS and activating TLR4 signaling in heart and brain, rather than merely following the disease. Because blocking TLR4 or restoring healthy microbiota reversed cardiac and depressive signs, microbiota modulation is proposed as a possible therapeutic strategy. Causation in humans remains unproven. This was a rat study with no accepted dysbiosis definition and no long-term safety data, and FMT carries infection risk, so clinical translation needs caution.